Corona vaccines against the South African variant B.1.351 no longer work properly, according to an Israeli study.
Tel Aviv – Do current vaccines protect against viral mutations? This is what the British variant B.1.1.7 looks like, which has almost completely displaced the “wild type” of SARS-Cowie-2 in many countries and Germany; A small loss of performance. The situation was different with the variant P.1.351, which first appeared in South Africa.
There is a bad news from Israel: the University of Tel Aviv and the Glitz Healthcare Organization – according to a recent study by Israel’s largest health insurance company – are eight times more likely to be infected than those not vaccinated in the South. However, overall this number is very low because the virus strain is not widespread in Israel, where 90 percent of the infections are due to the British variant. This study has not yet been pre-printed on medRxiV and has not yet been reviewed.
Vaccine protection of MRNA vaccines is not always effective in the South African corona variant
In Israel, 4.9 million people – about 53 percent of the population – have already received both vaccines. Only MRNA vaccines are injected there, most of which are from Biotech / Fiser, a small part of Moderna. For its study, the study team examined samples from 150 people who tested positive for the corona virus and found that they were somewhat asymptomatic but somewhat infected, although they had already received the first vaccine or both vaccines.
The study can be found from Israel www.medrxiv.org
“Based on the picture in the general population, we would have expected to find an epidemic with a South African variant, but we saw eight,” quoted Adi Stern, director of research at the Times of Israel, as saying: “This result did not make me happy.” The South African variant is able to break vaccine protection. Ron Poliser, director of research at the Glitz Healthcare organization, said the study was “very important” because it was based on data from the real world.
In early March, scientists at Ben Gurion University in the Negev found in laboratory tests that the vaccine from Biotech-Pfizer could not completely neutralize the South African variant and was less effective against strains with both characteristics. Carried with the British and South African variant.
Corona research with “real-world data” is getting worse than laboratory testing
The research team worked with samples from survivors of natural infections, as well as samples from completely vaccinated individuals and with the first dose for their study. These substances are called corona pseudoviruses in petri dish. At the time, it was concluded that there was a reduced but existing performance against the South African variant. This was more than an escape from the “wild type” infection of SARS-Cowie-2.
The results of the current study appear to be poor compared to “real-world data”. Ron Poliser of the Gladys Health Organization emphasizes the importance of being vigilant. This includes constantly wearing masks indoors and adhering to social distance. Epidemiological monitoring and systematic sequencing of viral material in corona-positive samples is essential.
So far, the South African variant is rare in Israel. Adi Stern, head of the study, estimates that only one percent of infections are caused. No other mutants were found in the study. Researchers suspect that conditions in Israel are more favorable to the British than in the South African variant.
The astrogenic vaccine does not protect against the South African corona variant
Weeks ago, a study from South Africa showed that a vaccine from AstraZeneca based on a different technology, such as the vector vaccine, was not protected against the South African variant. Vaccines for the disease were therefore discontinued in South Africa.
What worries me most about the study from Israel is that those who are vaccinated are more likely to be affected than those who are not affected by the South African variant – despite only eight cases in total. The study did not report whether people with P.1.1351 infection were infected with Govt-19 and how severe they were. Can the so-called “antigenic sin” come into play here? There are already isolated scientific works dedicated to this theory in relation to SARS-Cowie-2. It is important to prove that antigenic sin is a theory, not a proven fact.
Corona Vaccine: Will Antigenic Sin Implement? In the old version the immune system was fixed
Hypothesis: If the immune system is already infected with a virus and then encounters a new variant, it tends to develop antibodies only against the familiar structures from the original pathogen. According to this theory, the immune system will always make antibody versions against this antigen, which was known at first contact and can no longer be properly modified. The principle can be applied to a vaccine. In the worst case scenario, it can be harmful when one reveals a new variant of a virus because the immune system is repaired in the old version of the antigen. According to SARS-Cowie-2, this target system is spike protein; All approved vaccines are based on the original version of this protein.
Now, however, mutations of new viral variants occur precisely in this spike protein, on a much larger scale than the British one in the South African variant. Matthew Woodruff, an American immunologist at Emory University in Atlanta, writes about this problem in the British scientific journal “Conversation.” He worries that vaccine updates to suit new viral strains may be less effective for those who have already been vaccinated with the first vaccine. In this case, the immune memory may interfere with the development of a positive immune response to the vaccine. The scientific world needs to tackle this growing problem and work on “complex” vaccines that work against many strains of the virus. Research on such vaccines is already underway in the case of influenza. Knowledge from this should be immediately transferred to SARS-Cowie-2, according to the US Immunologist. (Pamela Durheffer)